Organ Preservation & Rescue Introducing TBM‑005

TBM-005 is an ex vivo additive for preservation and perfusion solutions designed to protect DCD and other high-risk donor organs from ischemic stress and reperfusion-related injury.

The untapped donor pool

As DCD donation grows, warm ischemia and tight assessment windows leave many recovered organs unusable.

Donation after brain death
(DBD)

8.4K Actual donors

34K organs recovered

26k organs Transplanted

Donation after cardiocirculatory death (DCD)

8.1K Actual donors

24K organs recovered

16K organs transplanted

Conversion is limited by ischemic injury, timing and organ-quality concerns.

Recovery gap

~41%

fewer recovered organs

DCD vs DBD donor pathway

Transplant conversion gap

~60%

fewer organs transplanted

DCD vs DBD donor pathway

Source: OPTN database 2025

Protecting organ quality, from recovery to transplant

Targa’s solution

A conditioning additive for better organ outcomes

TBM-005 is an ex vivo additive to preservation and perfusion solutions, designed to help maintain organ quality and reduce ischemia-reperfusion injury during recovery, storage, and perfusion. It’s workflow-compatible and temperature-flexible, integrating into existing transplant processes without new equipment or procedural changes.

Cold Treatment 4-10°C

During procurement

Added to flush and cold-storage solutions at organ procurement. Organ conditioning begins at the first point of ischemic exposure.

Warm perfusion 37°c

During EVLP

Integrated into machine perfusion solution during ex vivo assessment, supporting organ conditioning while function is evaluated.

Key Features

Designed for preservation and perfusion workflows
Developed as an additive to existing organ recovery solutions with no new hardware concept required
Can integrate into current procurement, storage, and ex vivo perfusion processes with temperature-flexible ex vivo use
Designed for cold preservation and warm perfusion settings
Supported by preclinical organ-recovery data

Advancing toward first-in-human
clinical validation

Clinical track record

A clinical execution platform rooted in transplant expertise

The team behind TBM-005 brings the scientific track record, institutional affiliations, and clinical infrastructure required to advance the program toward first-in-human evaluation.

First-in-human study

Targa’s Chief Medical Officer, Dr. Nicolas Noiseux, has led first-in-human trials in cell therapy for ischemic heart disease and heart failure at CHUM. The clinical team brings deep experience in translating experimental science into safe, validated human studies.

250+ peer-reviewed publications

Co-Founders Dr. Shant Der Sarkissian and Dr. Nicholas Noiseaux combine deep scientific expertise with hands-on experience across cardiovascular research, cell and gene therapy, and translational medicine.

Preclinical validation across multiple organ types

TBM-005 is supported by advanced small and large animal data across lung, liver and heart. Manufacturing R&D of TBM-005 is complete, and regulatory preparations are underway.

Workflow-compatible by design

TBM-005 is an ex vivo additive designed to integrate into existing preservation and perfusion workflows, with no new hardware required.

Clinical application

One treatment platform, multiple possibilities

Lung

Advancing toward first-in-human clinical validation in lung transplantation.

Heart

Promising organ protection signals in cardiac preclinical models. Heart transplantation is a key long-term expansion target.

Liver

Encouraging functional and injury-reduction data in preclinical models. Clinical evaluation is an active development priority.

Kidney

Future expansion opportunity. Evaluation planned through scientific collaboration.

Work with us

Amplifying what your platform can already do

TBM-005 is designed to complement existing preservation and perfusion workflows by adding an ex vivo organ-conditioning capability. It can support organ quality during recovery, preservation and perfusion without requiring new hardware or procedural changes.

For transplant
programs & OPOs

More usable organs. No workflow disruption.

TBM-005 is designed to support organ quality in DCD and marginal organs during preservation and perfusion. The result: more transplantable organs, improved graft outcomes, and new clinical options for patients currently without a match — without disrupting how your program operates today.

For device & solution
manufacturers

Strengthen your DCD program

We extend your device capabilities in DCD scenarios. TBM-005 integrates with your existing platform — additive, not competitive. For device and solution manufacturers, it may complement current offerings and support broader clinical utility in DCD and marginal organ use.

Frequently
Asked
Questions

What is TBM-005?callie@studiomfog.com2026-06-20T12:36:36-04:00

What is TBM-005?

TBM-005 is an ex vivo additive being developed by Targa Biomedical for use with organ preservation and perfusion solutions and systems. It is being developed to support the preservation and functional assessment of donor organs prior to transplantation, which may include DCD organs.

What is DCD organ transplantation?callie@studiomfog.com2026-06-20T12:36:53-04:00

What is DCD organ transplantation?

DCD stands for Donation after Circulatory Death. These are organs donated after circulatory function has stopped, rather than following brain death donation (DBD). DCD organs may experience warm ischemia, a period of reduced oxygen delivery that can affect organ quality and transplant suitability.

What is ischemia-reperfusion injury in organ transplantation?callie@studiomfog.com2026-06-20T12:37:00-04:00

What is ischemia-reperfusion injury in organ transplantation?

Ischemia-reperfusion injury can occur when an organ experiences reduced oxygen delivery followed by restoration of oxygenated perfusion. This process may contribute to cellular stress, inflammation, edema, and reduced organ function. DCD and other high-risk donor organs can be particularly vulnerable to these preservation and reperfusion-related stresses.

How does TBM-005 work with existing perfusion systems?callie@studiomfog.com2026-06-20T12:37:09-04:00

How does TBM-005 work with existing perfusion systems?

TBM-005 is being developed as an ex vivo additive intended for integration into existing organ preservation and perfusion workflows. The development approach is intended to support compatibility with current cold storage, flush, and ex vivo perfusion approaches without requiring any dedicated new perfusion device.

What organs can TBM-005 be used for?callie@studiomfog.com2026-06-20T12:38:06-04:00

What organs can TBM-005 be used for?

TBM-005 is currently advancing toward a first-in-human clinical study in lung transplantation. Additional preclinical programs are ongoing in liver, heart, and kidney preservation and perfusion.